Background: Patients with pathological stage IA lung adenocarcinoma (LUAD) are at risk of relapse. The value of the TNM staging system is limited in predicting recurrence. Our study aimed to develop a precise recurrence prediction model for stage IA LUAD. Materials and methods: Patients with pathological stage IA LUAD who received surgical treatment at Zhongshan Hospital Fudan University were retrospectively analyzed. Multivariate Cox proportional hazards regression models were used to create nomograms for recurrence-free survival (RFS). The predictive performance of the model was assessed using calibration plots and the concordance index (C-index). Results: The multivariate Cox regression analysis revealed that CTR (0.75 < CTR ≤ 1; HR = 9.882, 95% CI: 2.036–47.959, p = 0.004) and solid/micropapillary-predominance (SMPP; >5% and the most dominant) (HR = 4.743, 95% CI: 1.506–14.933, p = 0.008) were independent prognostic factors of RFS. These risk factors were used to construct a nomogram to predict postoperative recurrence in these patients. The C-index of the nomogram for predicting RFS was higher than that of the eighth T-stage system (0.873 for the nomogram and 0.643 for the eighth T stage). The nomogram also achieved good predictive performance for RFS with a well-fitted calibration curve. Conclusions: We developed and validated a nomogram based on CTR and SMP patterns for predicting postoperative recurrence in pathological stage IA LUAD. This model is simple to operate and has better predictive performance than the eighth T stage system, making it suitable for selecting further adjuvant treatment and follow-up.
Lung cancer remains the leading cause of cancer-related mortality worldwide, highlighting the critical need to identify key oncogenic drivers and develop effective therapeutic strategies. Here, we demonstrate that pre-mRNA processing factor 19 (PRPF19) is significantly upregulated in lung cancer tissues and correlates with poor clinical prognosis. Mechanistically, PRPF19 mediates linear (M1-linked) ubiquitylation of Citron Kinase (CIT), which is essential for CIT midbody localization and successful cytokinesis; PRPF19 knockdown induces cytokinesis failure, cell cycle arrest, and impaired proliferation. In parallel, PRPF19 promotes lysosomal degradation of p65 via linear ubiquitylation, thereby suppressing NF-κB signaling and CXCL10 expression. PRPF19 knockdown stabilizes p65, elevates CXCL10, and enhances CD8 + T cell infiltration and anti-tumor immunity in a CXCL10/CXCR3-dependent manner. Collectively, our findings establish PRPF19 as a dual function regulator governing both cytokinesis and immune evasion in lung cancer, revealing a promising therapeutic target and providing mechanistic basis for novel treatment strategies.